SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Abroad (travel likely)RecruitingPHASE2
Conditions
Ovarian Cancer Recurrent
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
St James's University Hospital, Leeds, Leeds, United Kingdom
Contact: Study coordinator (Amy Burkinshaw) · leedsth-tr.oncologydatamanagement@nhs.net · 01132068603Contact: Principal Investigator (Geoff Hall, Professor)Leicester Royal Infirmary, Leicester, Leicester, United Kingdom
Contact: Principal Investigator (Anu Gore)The Christie NHS Foundation Trust, Manchester, Manchester, United Kingdom
Contact: Principal Investigator (Lisa Barraclough)Gordon Jayson (Sub-investigator)Western General Hospital, Edinburgh, Scotland, United Kingdom
Contact: Principal Investigator (Charlie Gourley)Iain Phillips (Sub-investigator)The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Contact: Principal Investigator (Susana Banerjee)Alexandra Taylor (Sub-investigator)University College London Hospitals, London, UK, United Kingdom
Contact: Principal Investigator (Gemma Eminowicz)Rowan Miller (Sub-investigator)The Royal Marsden NHS Foundation Trust, London, United Kingdom
Contact: Principal Investigator (Susana Banerjee)Alexandra Taylor (Sub-investigator)
Study leads
Susana Banerjee
Principal Investigator
Royal Marsden NHS Foundation Trust